SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b)

(Amendment No. 6)¹

Insmed Incorporated
(Name of Issuer)
Common Stock
(Title of Class of Securities)
457669 20 8
(CUSIP Number)
December 31, 2005

(Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- o Rule 13d-1(b)
- ý Rule 13d-1(c)
- o Rule 13d-1(d)

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the *Notes*).

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

CUSIP No. 457669 20 8	13G	Page 2 of 10 Pages
1 NAME OF REPORT Biotechnology Value I.R.S. IDENTIFICAT		
2 CHECK THE APPRO	OPRIATE BOX IF A MEMBER OF A GROUP*	(a) ý (b) o
3 SEC USE ONLY		
4 CITIZENSHIP OR P	LACE OF ORGANIZATION	
Delaware		
NUMBER OF SHARES	5 SOLE VOTING POWER 0	
BENEFICIALLY OWNED BY	6 SHARED VOTING POWER 0	
EACH REPORTING PERSON	7 SOLE DISPOSITIVE POWER 0	
WITH:	8 SHARED DISPOSITIVE POWER 0	
9 AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
0		
10 CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	o
11 PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
0%		
12 TYPE OF REPORT	TING PERSON*	
PN		

CUSIP No. 457669 20 8	13G	Page 3 of 10 Pages
1 NAME OF REPORT Biotechnology Value I.R.S. IDENTIFICAT		
2 CHECK THE APPRO	OPRIATE BOX IF A MEMBER OF A GROUP*	(a) ý (b) o
3 SEC USE ONLY		
4 CITIZENSHIP OR P	LACE OF ORGANIZATION	
Delaware		
NUMBER OF SHARES	5 SOLE VOTING POWER 0	
BENEFICIALLY OWNED BY	6 SHARED VOTING POWER 0	
EACH REPORTING PERSON	7 SOLE DISPOSITIVE POWER 0	
WITH:	8 SHARED DISPOSITIVE POWER 0	
9 AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
0		
10 CHECK BOX IF TH	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	o
11 PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
0%		
12 TYPE OF REPORT	ING PERSON*	
PN		

CUSIP No. 457669 20 8	13G	Page 4 of 10 Pages
1 NAME OF REPORTI BVF Investments, L. I.R.S. IDENTIFICAT		
2 CHECK THE APPRO	PRIATE BOX IF A MEMBER OF A GROUP*	(a) ý (b) o
3 SEC USE ONLY		
4 CITIZENSHIP OR PI	LACE OF ORGANIZATION	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING	5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 0 7 SOLE DISPOSITIVE POWER 0	
PERSON WITH:	8 SHARED DISPOSITIVE POWER 0	
9 AGGREGATE AMO	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10 CHECK BOX IF TH	IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	О
11 PERCENT OF CLA 0%	SS REPRESENTED BY AMOUNT IN ROW (9)	
12 TYPE OF REPORT	ING PERSON*	

CUSIP No. 457669 20 8	13G	Page 5 of 10 Pages
1 NAME OF REPORTI Investment 10, L.L.C I.R.S. IDENTIFICAT		
2 CHECK THE APPRO	PRIATE BOX IF A MEMBER OF A GROUP*	(a) ý (b) o
3 SEC USE ONLY		
4 CITIZENSHIP OR PI	LACE OF ORGANIZATION	
NUMBER OF	5 SOLE VOTING POWER 0	
SHARES BENEFICIALLY OWNED BY	6 SHARED VOTING POWER 0	
EACH REPORTING PERSON	7 SOLE DISPOSITIVE POWER 0	
WITH:	8 SHARED DISPOSITIVE POWER 0	
9 AGGREGATE AMO	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
0		
10 CHECK BOX IF TH	IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	0
11 PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
0%		
12 TYPE OF REPORT	ING PERSON*	
00		

CUSIP No. 457669 20 8	13G	Page 6 of 10 Pages
1 NAME OF REPORTI BVF Partners L.P. I.R.S. IDENTIFICAT	ING PERSON: ION NO. OF ABOVE PERSON (ENTITIES ONLY):	
2 CHECK THE APPRO	DPRIATE BOX IF A MEMBER OF A GROUP*	(a) ý (b) o
3 SEC USE ONLY		
4 CITIZENSHIP OR PI Delaware	LACE OF ORGANIZATION	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 9 AGGREGATE AMO	5 SOLE VOTING POWER 6 SHARED VOTING POWER 7 SOLE DISPOSITIVE POWER 0 SHARED DISPOSITIVE POWER 0 OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	* o
11 PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
12 TYPE OF REPORT	ING PERSON*	

CUSIP No. 457669 20 8	13G	Page 7 of 10 Pages
1 NAME OF REPORTI BVF Inc. I.R.S. IDENTIFICAT	NG PERSON: ION NO. OF ABOVE PERSON (ENTITIES ONLY):	
2 CHECK THE APPRO	PRIATE BOX IF A MEMBER OF A GROUP*	(a) ý (b) o
3 SEC USE ONLY		
4 CITIZENSHIP OR PI Delaware	LACE OF ORGANIZATION	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH	5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 0 7 SOLE DISPOSITIVE POWER	
REPORTING PERSON WITH:	8 SHARED DISPOSITIVE POWER 0	
9 AGGREGATE AMO 0	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10 CHECK BOX IF TH	IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	0
11 PERCENT OF CLA 0%	SS REPRESENTED BY AMOUNT IN ROW (9)	
12 TYPE OF REPORTE	ING PERSON*	

CUSIP No. 457669 20 8 Page 8 of 10 Pages

ITEM 1(a). NAME OF ISSUER:

Insmed Incorporated ("Insmed")

ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

4851 Lake Brook Drive Glen Allen, Virginia 23060

ITEM 2(a). NAME OF PERSON FILING:

This Amendment No. 6 to Schedule 13G is being filed on behalf of the following persons (the "Reporting Persons"):

- (i) Biotechnology Value Fund, L.P. ("BVF")
- (ii) Biotechnology Value Fund II, L.P. ("BVF2")
- (iii)
- BVF Investments, L.L.C. ("Investments") (iv)
- Investment 10, L.L.C. ("ILL10")
- (v) BVF Partners L.P. ("Partners")
- (vi) BVF Inc. ("BVF Inc.")

ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE:

The principal business office of the Reporting Persons comprising the group filing this Amendment No. 6 to Schedule 13G is located at 900 North Michigan Avenue, Suite 1100, Chicago, Illinois, 60611.

ITEM 2(c). CITIZENSHIP:

BVF: a Delaware limited partnership
BVF2: a Delaware limited partnership
Investments: a Delaware limited liability company
ILL10: an Illinois limited liability company
Partners: a Delaware limited partnership
BVF Inc.: a Delaware corporation

ITEM 2(d). TITLE OF CLASS OF SECURITIES:

This Amendment No. 6 to Schedule 13G is being filed with respect to the common stock, par value \$0.01 per share (the "Common Stock"), of Insmed. As of January 18, 2006, BVF, BVF2, Investments, ILL10, Partners and BVF Inc. no longer beneficially own any shares of Common Stock

ITEM 2(e). CUSIP Number:

457669 20 8

CUSIP No. 457669 20 8 Page 9 of 10 Pages

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS: One of the following

Not applicable as this Amendment No. 6 to Schedule 13G is filed pursuant to Rule 13d-1(c).

ITEM 4. OWNERSHIP:

The information in items 1 and 5 through 11 on the cover pages (pp. 2 - 7) on this Amendment No. 6 to Schedule 13G is hereby incorporated by reference.

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities check the following. X

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

Not applicable.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:

Not applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP:

Not applicable.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP:

Not applicable.

CUSIP No. 457669 20 8 Page 10 of 10 Pages

ITEM 10. CERTIFICATION

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 10, 2006

BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

Mark N. Lampert President

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

Mark N. Lampert President

BVF INVESTMENTS, L.L.C.

By: BVF Partners L.P., its manager

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

Mark N. Lampert President

INVESTMENT 10, L.L.C.

By: BVF Partners L.P., its attorney-in-fact

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

Edgar Filing: INSMED INC - Form SC 13G/A

Mark N. Lampert President

BVF PARTNERS L.P.

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

Mark N. Lampert President

BVF INC.

By: /s/ MARK N. LAMPERT

Mark N. Lampert President